Total Payments
$1,811
2024 Payments
$430.55
Companies
17
Transactions
83
Medicare Patients
785
Medicare Billing
$143,168
Payment Breakdown by Category
Food & Beverage$1,712 (94.5%)
Education$99.00 (5.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,712 | 82 | 94.5% |
| Education | $99.00 | 1 | 5.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TESARO, Inc. | $393.72 | 9 | $0 (2019) |
| Clovis Oncology, Inc. | $387.29 | 22 | $0 (2022) |
| Merck Sharp & Dohme LLC | $305.43 | 16 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $122.73 | 6 | $0 (2024) |
| Genmab U.S., Inc. | $121.75 | 8 | $0 (2024) |
| GlaxoSmithKline, LLC. | $94.54 | 4 | $0 (2023) |
| Eisai Inc. | $93.98 | 4 | $0 (2024) |
| Astellas Pharma US Inc | $58.35 | 3 | $0 (2024) |
| Tempus AI, Inc | $51.97 | 2 | $0 (2024) |
| ABBVIE INC. | $47.36 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $430.55 | 21 | Merck Sharp & Dohme LLC ($83.52) |
| 2023 | $159.05 | 7 | Merck Sharp & Dohme LLC ($52.47) |
| 2022 | $44.75 | 3 | Clovis Oncology, Inc. ($23.11) |
| 2021 | $127.14 | 8 | Clovis Oncology, Inc. ($51.31) |
| 2020 | $22.72 | 3 | Clovis Oncology, Inc. ($22.72) |
| 2019 | $344.00 | 17 | Clovis Oncology, Inc. ($172.62) |
| 2018 | $422.86 | 15 | TESARO, Inc. ($190.39) |
| 2017 | $260.15 | 9 | TESARO, Inc. ($166.75) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $22.79 | General |
| 11/15/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $29.86 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Biological | ||||||
| 09/30/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.18 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.27 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.54 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Biological | ||||||
| 07/22/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: Biological | ||||||
| 07/15/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $0.86 | General |
| Category: Oncology | ||||||
| 07/14/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $2.54 | General |
| Category: Oncology | ||||||
| 07/12/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 07/01/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.85 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $4.36 | General |
| Category: Oncology | ||||||
| 05/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: ONCOLOGY | ||||||
| 04/05/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: HORMONE THERAPY | ||||||
| 12/04/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $28.55 | General |
| Category: Oncology | ||||||
| 10/09/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $21.90 | General |
| Category: Oncology | ||||||
| 09/18/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 193 | 221 | $110,873 | $36,872 |
| 2022 | 8 | 190 | 207 | $101,618 | $33,769 |
| 2021 | 8 | 225 | 240 | $151,364 | $41,420 |
| 2020 | 8 | 177 | 203 | $88,777 | $31,107 |
Total Patients
785
Total Services
871
Medicare Billing
$143,168
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 21 | 21 | $38,136 | $13,637 | 35.8% |
| 58661 | Removal of ovaries and/or tubes using an endoscope | Facility | 2023 | 12 | 12 | $19,082 | $7,367 | 38.6% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2023 | 16 | 16 | $21,200 | $4,170 | 19.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 42 | 42 | $9,198 | $3,575 | 38.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 39 | $6,942 | $2,598 | 37.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 45 | 58 | $6,322 | $2,066 | 32.7% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2023 | 17 | 18 | $5,058 | $1,739 | 34.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $4,935 | $1,721 | 34.9% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 24 | 24 | $43,584 | $16,752 | 38.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $10,857 | $4,178 | 38.5% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2022 | 15 | 15 | $19,875 | $3,704 | 18.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 29 | 29 | $6,351 | $2,381 | 37.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 30 | 37 | $6,586 | $2,162 | 32.8% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 15 | 15 | $6,463 | $2,021 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 14 | $3,542 | $1,379 | 38.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 31 | 40 | $4,360 | $1,191 | 27.3% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2021 | 31 | 31 | $56,153 | $20,943 | 37.3% |
| 38571 | Removal of total lymph nodes of both sides of pelvis using an endoscope | Facility | 2021 | 19 | 19 | $25,170 | $5,035 | 20.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $11,798 | $4,514 | 38.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 37 | 41 | $7,198 | $2,609 | 36.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 31 | 31 | $6,760 | $2,452 | 36.3% |
| 38900 | Lymph node imaging during surgery | Facility | 2021 | 17 | 17 | $5,872 | $2,133 | 36.3% |
| 58558 | Biopsy and/or removal of polyp of the uterus using an endoscope | Facility | 2021 | 12 | 12 | $32,732 | $1,886 | 5.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 42 | 53 | $5,681 | $1,847 | 32.5% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2020 | 22 | 22 | $37,642 | $14,917 | 39.6% |
About Dr. Stephen Andrews, M.D
Dr. Stephen Andrews, M.D is a Gynecologic Oncology healthcare provider based in Akron, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255328845.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Andrews, M.D has received a total of $1,811 in payments from pharmaceutical and medical device companies, with $430.55 received in 2024. These payments were reported across 83 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,712).
As a Medicare-enrolled provider, Andrews has provided services to 785 Medicare beneficiaries, totaling 871 services with total Medicare billing of $143,168. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Akron, OH
- Active Since 09/29/2005
- Last Updated 11/11/2011
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1255328845
Products in Payments
- ZEJULA (Drug) $435.94
- Rubraca (Drug) $366.80
- KEYTRUDA (Biological) $253.85
- LYNPARZA (Drug) $122.73
- Tivdak (Drug) $105.15
- Lenvima (Drug) $93.98
- Veozah (Drug) $58.35
- ELAHERE (Drug) $47.36
- JEMPERLI (Biological) $32.79
- MYFEMBREE (Drug) $24.28
- Neulasta (Biological) $22.01
- MYRISK (Device) $21.91
- SANCUSO (Drug) $21.77
- VARUBI (Drug) $19.53
- TIVDAK (Drug) $16.60
- LARTRUVO (Drug) $16.37
- LYNPARZA (Biological) $14.94
- Bonjesta (Drug) $14.47
- Avastin (Biological) $13.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.